PE20160658A1 - Nucleosidos sustituidos, nucleotidos y analogos de los mismos - Google Patents
Nucleosidos sustituidos, nucleotidos y analogos de los mismosInfo
- Publication number
- PE20160658A1 PE20160658A1 PE2016000494A PE2016000494A PE20160658A1 PE 20160658 A1 PE20160658 A1 PE 20160658A1 PE 2016000494 A PE2016000494 A PE 2016000494A PE 2016000494 A PE2016000494 A PE 2016000494A PE 20160658 A1 PE20160658 A1 PE 20160658A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- absent
- alkyl
- nucleotides
- analogs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a nucleosidos, nucleotidos y analogos de nucleotidos de formula (I), o sales farmaceuticamente aceptables de los mismos, que se caracterizan porque B1A es una base heterociclica opcionalmente sustituida con un grupo amino protegido, entre otros; ambas lineas discontinuas (-----) estan ausentes, o ambas son un enlace simple; Ra1 y Ra2 son independientemente H o deuterio; RA es H, alquilo C1C3, CN, entre otros; R2A es H, halo, alquilo C1C4, entre otros; y R5A es H, halo, OH, alquilo C1C6, entre otros. Cuando ambas ----- estan ausentes, Z1 esta ausente; O1 es OR1A, donde R1A es H, acilo, aminoacido Oenlazado, P(O)(OH)2, P(O)H(OH), entre otros; R3A es H, halo, OH, entre otros; y R4A es H, OH, halo, N3, NH2, entre otros. Cuando ambas ----- son un enlace simple, Z1 es >P(O)OH, >P(S)OH, entre otros; O1 es O; R3A es O; y R4 es H, OH, halo, N3, NH2, entre otros. Tambien se refiere a composiciones farmaceuticas que comprenden dichos compuestos de formula (I). Los compuestos de la invencion son utiles en el tratamiento de infecciones virales causadas por picornavirus o flaviviridae.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361890136P | 2013-10-11 | 2013-10-11 | |
US201462016288P | 2014-06-24 | 2014-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20160658A1 true PE20160658A1 (es) | 2016-08-05 |
Family
ID=52810177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016000494A PE20160658A1 (es) | 2013-10-11 | 2014-10-09 | Nucleosidos sustituidos, nucleotidos y analogos de los mismos |
Country Status (16)
Country | Link |
---|---|
US (2) | US9862743B2 (es) |
EP (1) | EP3055319A4 (es) |
JP (1) | JP6562908B2 (es) |
KR (1) | KR102314960B1 (es) |
CN (2) | CN105829333A (es) |
AU (3) | AU2014331863C1 (es) |
CA (1) | CA2927010C (es) |
CL (1) | CL2016000805A1 (es) |
EA (1) | EA201690526A1 (es) |
IL (1) | IL245014B (es) |
MX (2) | MX2016004558A (es) |
PE (1) | PE20160658A1 (es) |
PH (1) | PH12016500660A1 (es) |
SG (2) | SG11201602595TA (es) |
TW (1) | TW201524990A (es) |
WO (1) | WO2015054465A1 (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP3584A (en) | 2010-09-22 | 2016-02-09 | Alios Biopharma Inc | Substituted nucleotide analogs |
US8877731B2 (en) | 2010-09-22 | 2014-11-04 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
EP2655392B1 (en) | 2010-12-22 | 2018-04-18 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
LT2794627T (lt) | 2011-12-22 | 2019-01-10 | Alios Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
UY34824A (es) | 2012-05-25 | 2013-11-29 | Janssen R & D Ireland | Nucleósidos de espirooxetano de uracilo |
CN104903339A (zh) * | 2012-11-16 | 2015-09-09 | 卡迪夫大学学院顾问有限公司 | 用于制备核苷前体药物的方法 |
SI2935303T1 (sl) * | 2012-12-21 | 2021-08-31 | Janssen Biopharma, Inc. | 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV |
WO2014100498A1 (en) | 2012-12-21 | 2014-06-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
AR099632A1 (es) | 2013-04-05 | 2016-08-10 | Alios Biopharma Inc | Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos |
US9422322B2 (en) | 2013-06-26 | 2016-08-23 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
AU2014302711A1 (en) | 2013-06-26 | 2015-12-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
JP6562908B2 (ja) | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク. | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
CR20160400A (es) * | 2014-02-06 | 2016-11-07 | Riboscience Llc | Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza |
CA2952959C (en) | 2014-06-24 | 2023-03-07 | Alios Biopharma, Inc. | Use of nucleosides and nucleotides to treat filoviridae viral infection |
LT3160476T (lt) | 2014-06-24 | 2021-04-12 | Janssen Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme |
EA201692473A1 (ru) * | 2014-06-24 | 2017-03-31 | Элиос Биофарма, Инк. | Способы получения замещенных нуклеотидных аналогов |
TWI673283B (zh) * | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | 2’-氯胺基嘧啶酮及嘧啶二酮核苷類 |
MA40149A1 (fr) * | 2014-09-26 | 2019-04-30 | Riboscience Llc | Dérivés de nucléoside 4'-vinyle substitués utiles en tant qu'inhibiteurs de la réplication due l'arn du virus respiratoire syncytial |
CN107108681B (zh) | 2014-10-28 | 2021-04-06 | 詹森生物制药有限公司 | 制备取代的核苷类似物的方法 |
MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
HUE056470T2 (hu) | 2014-12-26 | 2022-02-28 | Univ Emory | Vírusellenes N4-Hidroxicitidin származékok |
CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
US10208045B2 (en) | 2015-03-11 | 2019-02-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
JP6743135B2 (ja) | 2015-09-02 | 2020-08-19 | アッヴィ・インコーポレイテッド | 抗ウィルス性テトラヒドロフラン誘導体 |
TW201718618A (zh) * | 2015-09-18 | 2017-06-01 | 田邊三菱製藥股份有限公司 | 架橋型核酸GuNA,其製造方法,及中間體化合物 |
KR101785475B1 (ko) | 2015-12-23 | 2017-10-16 | (주)다산메디켐 | 항바이러스성 화합물 |
US9988416B2 (en) * | 2016-03-24 | 2018-06-05 | Novartis Ag | Alkynyl nucleoside analogs as inhibitors of human rhinovirus |
JP6567781B2 (ja) * | 2016-03-31 | 2019-08-28 | ロマーク ラボラトリーズ,リミティド カンパニー | ウイルス感染症の治療用チアゾリド化合物 |
EP3448392A4 (en) * | 2016-04-28 | 2020-01-15 | Emory University | ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
CN106279321A (zh) * | 2016-08-09 | 2017-01-04 | 南京医科大学 | 吉西他滨ProTide乏氧活化前药及其应用 |
EP3497111A2 (en) | 2016-08-12 | 2019-06-19 | Janssen BioPharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
JP2019526596A (ja) | 2016-09-07 | 2019-09-19 | アテア ファーマシューティカルズ, インコーポレイテッド | Rnaウイルス治療に対する2’−置換−n6−置換プリンヌクレオチド |
JP7016170B2 (ja) * | 2016-12-16 | 2022-02-04 | 国立大学法人東海国立大学機構 | ヌクレオシド誘導体及びその利用 |
CN108299532B (zh) * | 2016-12-29 | 2020-12-22 | 广东东阳光药业有限公司 | 一种抗病毒核苷类似物前药及其组合物、用途 |
KR102335193B1 (ko) | 2017-02-01 | 2021-12-03 | 아테아 파마슈티컬즈, 인크. | C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염 |
GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
TW201919648A (zh) | 2017-07-11 | 2019-06-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物 |
CN111491634A (zh) | 2017-07-31 | 2020-08-04 | 詹纽瑞治疗公司 | 有机磷酸酯衍生物 |
WO2019053696A1 (en) * | 2017-09-18 | 2019-03-21 | Alios Biopharma, Inc. | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF |
JP7173467B2 (ja) | 2017-10-31 | 2022-11-16 | ヤマサ醤油株式会社 | ヌクレオシド誘導体及びその利用 |
GB2590198B (en) | 2017-12-07 | 2022-02-23 | Univ Emory | N4-hydroxycytidine derivatives and anti-viral uses related thereto |
GB2589205B (en) * | 2018-03-07 | 2023-05-24 | Univ Emory | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
WO2019237297A1 (en) * | 2018-06-14 | 2019-12-19 | Janssen Pharmaceuticals, Inc. | Processes for preparing compounds/intermediates useful in the treatment of viral infections |
US11834469B2 (en) | 2018-08-06 | 2023-12-05 | Skylark Bioscience Llc | AMP-activated protein kinase activating compounds and uses thereof |
WO2020041051A1 (en) * | 2018-08-20 | 2020-02-27 | Cure Biopharma Inc. | Gemcitabine prodrugs |
US11708637B2 (en) | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
CA3153281A1 (en) * | 2019-10-08 | 2021-07-08 | George R. Painter | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
WO2021101469A1 (en) * | 2019-11-21 | 2021-05-27 | Gaziantep Universitesi Rektorlugu | A drug for anticancer and antiviral treatment and synthesis method thereof |
JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ, インコーポレイテッド | SARS CoV-2感染を治療するための方法 |
WO2021168004A1 (en) | 2020-02-18 | 2021-08-26 | Gilead Sciences, Inc. | Antiviral compounds |
TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
AU2021251689B2 (en) | 2020-04-06 | 2024-06-13 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
EP4172160A2 (en) | 2020-06-24 | 2023-05-03 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
KR20230057419A (ko) | 2020-08-24 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | 인지질 화합물 및 이의 용도 |
WO2022047065A2 (en) | 2020-08-27 | 2022-03-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
CN114796256B (zh) * | 2021-01-29 | 2023-12-08 | 武汉大学 | 环腺苷酸类化合物在制备抗寨卡病毒药物中的应用 |
EP4323362A1 (en) | 2021-04-16 | 2024-02-21 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
CN116554249A (zh) * | 2022-01-28 | 2023-08-08 | 北京恩泰伟医药科技有限公司 | 抗病毒化合物及其用途 |
TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
CN115322170B (zh) * | 2022-08-29 | 2023-06-02 | 苏州华一新能源科技股份有限公司 | 一种硫酸乙烯酯的制备方法 |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS552601A (en) | 1978-06-20 | 1980-01-10 | Yamasa Shoyu Co Ltd | Anti-tumor agent for non-injection use |
US5674998A (en) | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
US6110901A (en) * | 1990-07-03 | 2000-08-29 | American Cyanamid Company | Method for treating RNA viral infections by using RNA chain terminators |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
JPH07242544A (ja) | 1994-03-01 | 1995-09-19 | Takeda Chem Ind Ltd | 抗腫瘍剤 |
ES2172764T3 (es) | 1996-01-23 | 2002-10-01 | Icn Pharmaceuticals | Modulacion de la expresion de citoquina th1/th2 por ribavirina en linfocitos t activados. |
DE69721339T2 (de) | 1996-10-16 | 2004-01-22 | Ribapharm, Inc., Costa Mesa | Monozyklische l-nukleoside, analoga und ihre anwendungen |
ATE271063T1 (de) | 1996-10-16 | 2004-07-15 | Icn Pharmaceuticals | Purin-l-nukleoside, deren analoga und verwendungen |
US20030064945A1 (en) | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
AU4322799A (en) | 1998-05-28 | 1999-12-13 | Incara Pharmaceuticals Corp. | Carbohydrate-based scaffold compounds, combinatorial libraries and methods for their construction |
DE19855963A1 (de) | 1998-12-04 | 2000-06-08 | Herbert Schott | Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung |
WO2000069876A1 (en) | 1999-05-12 | 2000-11-23 | Yamasa Corporation | 4'-c-ethynyl pyrimidine nucleosides |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
EP2360166A1 (en) | 2001-01-22 | 2011-08-24 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
US20030124513A1 (en) | 2001-05-29 | 2003-07-03 | Mcswiggen James | Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV |
WO2003070912A2 (en) | 2001-06-06 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
US6962991B2 (en) | 2001-09-12 | 2005-11-08 | Epoch Biosciences, Inc. | Process for the synthesis of pyrazolopyrimidines |
JP2005536440A (ja) * | 2001-09-28 | 2005-12-02 | イデニクス(ケイマン)リミテツド | 4’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物 |
US7138376B2 (en) | 2001-09-28 | 2006-11-21 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
US7125982B1 (en) | 2001-12-05 | 2006-10-24 | Frayne Consultants | Microbial production of nuclease resistant DNA, RNA, and oligo mixtures |
US20070032448A1 (en) | 2002-01-17 | 2007-02-08 | Zhi Hong | Sugar modified nucleosides as viral replication inhibitors |
WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
EP1476169B1 (en) | 2002-02-13 | 2013-03-20 | Merck Sharp & Dohme Corp. | Inhibiting orthopoxvirus replication with nucleoside compounds |
WO2003073989A2 (en) | 2002-02-28 | 2003-09-12 | Biota, Inc. | Nucleoside 5'-monophosphate mimics and their prodrugs |
AU2003237249A1 (en) | 2002-05-24 | 2003-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
AU2003241621A1 (en) | 2002-05-24 | 2003-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
JP2005530843A (ja) | 2002-06-21 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | Rna依存性rnaウィルスポリメラーゼ阻害剤としてのヌクレオシド誘導体 |
JP2006512288A (ja) | 2002-06-27 | 2006-04-13 | メルク エンド カムパニー インコーポレーテッド | Rna依存性rnaウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体 |
WO2004003000A2 (en) | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections |
PL374831A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
JP2005533108A (ja) | 2002-07-16 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Rna依存性rnaウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体 |
WO2004014312A2 (en) | 2002-08-08 | 2004-02-19 | Sirna Therapeutics, Inc. | Small-mer compositions and methods of use |
WO2004037159A2 (en) | 2002-10-23 | 2004-05-06 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
US20040229840A1 (en) | 2002-10-29 | 2004-11-18 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US7393954B2 (en) | 2002-12-12 | 2008-07-01 | Reliable Biopharmaceutical Corporation | Process for the production of pentostatin aglycone and pentostatin |
AU2003225705A1 (en) | 2003-03-07 | 2004-09-30 | Ribapharm Inc. | Cytidine analogs and methods of use |
US7691603B2 (en) | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
WO2005020884A2 (en) * | 2003-05-14 | 2005-03-10 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
EP1633766B1 (en) | 2003-05-30 | 2019-03-06 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
EP1644479A4 (en) | 2003-06-16 | 2008-04-23 | Mark W Grinstaff | MACROMOLECULES AND FUNCTIONAL SYNTHETIC MOLECULES FOR GENES ADMINISTRATION |
CN1852915A (zh) * | 2003-07-25 | 2006-10-25 | 艾登尼科斯(开曼)有限公司 | 治疗包括丙型肝炎的黄病毒科病毒所致疾病的嘌呤核苷类似物 |
DE602004029904D1 (de) | 2003-08-27 | 2010-12-16 | Biota Scient Management | Neue tricyclische nukleoside oder nukleotide als therapeutische mittel |
WO2006033709A2 (en) * | 2004-07-29 | 2006-03-30 | Metabasis Therapeutics, Inc. | Novel nucleoside derivatives |
WO2006000922A2 (en) | 2004-06-23 | 2006-01-05 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
WO2006063717A2 (en) | 2004-12-16 | 2006-06-22 | Febit Biotech Gmbh | Polymerase-independent analysis of the sequence of polynucleotides |
US8802840B2 (en) | 2005-03-08 | 2014-08-12 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
JP2008535932A (ja) | 2005-03-09 | 2008-09-04 | イデニクス(ケイマン)リミテツド | 抗ウィルス剤としての非天然塩基を有するヌクレオシド |
US20060229265A1 (en) | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
CA2609342A1 (en) | 2005-04-26 | 2006-11-02 | Andrei L. Gartel | Nucleoside compounds and methods of use thereof |
WO2007020018A1 (en) | 2005-08-12 | 2007-02-22 | Universite Libre De Bruxelles | Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
CA2618335C (en) | 2005-08-15 | 2015-03-31 | F.Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4'-substituted pronucleotides |
NZ609146A (en) | 2005-09-26 | 2014-08-29 | Gilead Pharmasset Llc | Modified 4’-nucleosides as antiviral agents |
WO2007113538A1 (en) | 2006-04-03 | 2007-10-11 | Astrazeneca Ab | Substituted adenines and the uses thereof |
GB0614947D0 (en) | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US8071568B2 (en) | 2007-01-05 | 2011-12-06 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
EP2114980B1 (en) | 2007-01-12 | 2012-06-27 | BioCryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
US20120135091A1 (en) | 2007-01-18 | 2012-05-31 | Roth Mark B | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
US20080207554A1 (en) | 2007-01-31 | 2008-08-28 | Alios Biopharma, Inc. | 2-5A Analogs and their Methods of Use |
JP2008214305A (ja) | 2007-03-07 | 2008-09-18 | Kotobuki Seiyaku Kk | 置換アミン誘導体及びこれを有効成分とする医薬組成物 |
CN101765369A (zh) | 2007-03-19 | 2010-06-30 | 俄勒冈州由俄勒冈州立大学代表州高等教育委员会行使 | 曼尼希碱n-氧化物药物 |
WO2008117047A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolo[3, 4-d]pyrimidine derivatives as antibacterial compounds |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US20080255038A1 (en) | 2007-04-11 | 2008-10-16 | Samuel Earl Hopkins | Pharmaceutical compositions |
EP1980568A1 (de) | 2007-04-13 | 2008-10-15 | Eberhard Karls Universität Tübingen | Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung |
DK2014771T3 (en) | 2007-06-25 | 2015-03-09 | Anadys Pharmaceuticals Inc | Continuous process for the enzymatic hydrolysis |
GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
CN101889085A (zh) | 2007-12-07 | 2010-11-17 | 弗·哈夫曼-拉罗切有限公司 | Hcv ns3蛋白酶复制子穿梭载体 |
WO2009086192A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents |
WO2009086201A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents |
ATE551342T1 (de) | 2008-02-22 | 2012-04-15 | Irm Llc | Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer |
US8815906B2 (en) | 2008-03-19 | 2014-08-26 | Chembridge Corporation | Tyrosine kinase inhibitors |
WO2009129120A2 (en) | 2008-04-15 | 2009-10-22 | Rfs Pharma, Llc | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
WO2010015643A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
GB0815968D0 (en) | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
EP2332953A1 (en) | 2008-09-05 | 2011-06-15 | Kotobuki Pharmaceutical Co., Ltd. | Substituted amine derivative and medicinal composition comprising same as the active ingredient |
WO2010030858A1 (en) | 2008-09-15 | 2010-03-18 | Enanta Pharmaceuticals, Inc. | 4'-allene-substituted nucleoside derivatives |
US20100099079A1 (en) | 2008-09-26 | 2010-04-22 | Uprichard Susan L | Non-dividing cell-based assay for high throughput antiviral compound screening |
JP5793084B2 (ja) * | 2008-12-23 | 2015-10-14 | ギリアド ファーマセット エルエルシー | プリンヌクレオシドの合成 |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
JP2012517443A (ja) | 2009-02-06 | 2012-08-02 | アールエフエス ファーマ,エルエルシー | 癌及びウイルス感染の治療のためのプリンヌクレオシド一リン酸プロドラッグ |
WO2010108135A1 (en) | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
CN102421293A (zh) | 2009-03-20 | 2012-04-18 | 艾丽奥斯生物制药有限公司 | 取代的核苷和核苷酸类似物 |
RS57045B1 (sr) | 2009-05-08 | 2018-05-31 | Astellas Pharma Inc | Jedinjenje diamino heterocikličnog karboksamida |
EP2264169A1 (en) | 2009-06-15 | 2010-12-22 | Qiagen GmbH | Modified siNA |
US20100331397A1 (en) | 2009-06-24 | 2010-12-30 | Alios Biopharma, Inc. | 2-5a analogs and their methods of use |
US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
US20150018301A1 (en) | 2009-11-06 | 2015-01-15 | The Johns Hopkins University | LRRK-2-Mediated Neuronal Toxicity |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
KR20200052384A (ko) | 2010-07-19 | 2020-05-14 | 길리애드 사이언시즈, 인코포레이티드 | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 |
WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
US8877731B2 (en) | 2010-09-22 | 2014-11-04 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
AP3584A (en) | 2010-09-22 | 2016-02-09 | Alios Biopharma Inc | Substituted nucleotide analogs |
AR083221A1 (es) | 2010-09-29 | 2013-02-06 | Univ Nac Quilmes | Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato |
CN102516339B (zh) | 2010-10-21 | 2014-03-19 | 四川大学华西医院 | 嘧啶并嘧啶化合物及其核苷类似衍生物和制备方法及用途 |
US9505798B2 (en) | 2010-11-29 | 2016-11-29 | New York University | Steroid compounds as RORyt modulators and uses thereof |
EP2655392B1 (en) | 2010-12-22 | 2018-04-18 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
US9095599B2 (en) | 2011-01-03 | 2015-08-04 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
EP2696681B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US8877733B2 (en) | 2011-04-13 | 2014-11-04 | Gilead Sciences, Inc. | 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment |
EP2739154B1 (en) | 2011-08-01 | 2018-06-27 | MBC Pharma, Inc. | Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates |
CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
WO2013044030A1 (en) | 2011-09-23 | 2013-03-28 | Enanta Pharmaceuticals, Inc. | 2'-chloroacetylenyl substituted nucleoside derivatives |
AU2012357940B2 (en) | 2011-12-20 | 2017-02-16 | Riboscience Llc | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
LT2794627T (lt) | 2011-12-22 | 2019-01-10 | Alios Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
NZ630800A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Methods of preparing substituted nucleotide analogs |
UA113980C2 (uk) | 2012-03-21 | 2017-04-10 | Аліос Біофарма, Інк. | Заміщені нуклеозиди, нуклеотиди і їх аналоги |
WO2013142159A1 (en) * | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
CN102816197B (zh) | 2012-08-24 | 2015-04-29 | 四川大学华西医院 | 一种新的嘧啶并嘧啶类核苷类似物、制备方法及其形成的超分子结构和应用 |
MX2015005500A (es) | 2012-10-29 | 2016-02-09 | Cocrystal Pharma Inc | Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer. |
WO2014099941A1 (en) * | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
WO2014100498A1 (en) | 2012-12-21 | 2014-06-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
SI2935303T1 (sl) | 2012-12-21 | 2021-08-31 | Janssen Biopharma, Inc. | 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV |
TW201526899A (zh) | 2013-02-28 | 2015-07-16 | Alios Biopharma Inc | 醫藥組成物 |
WO2014164533A1 (en) | 2013-03-11 | 2014-10-09 | Vertex Pharmaceuticals Incorporated | Methods of stereoselective synthesis of substituted nucleoside analogs |
AR099632A1 (es) * | 2013-04-05 | 2016-08-10 | Alios Biopharma Inc | Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos |
CN105307662B (zh) * | 2013-05-16 | 2019-06-04 | 里博科学有限责任公司 | 4’-氟-2’-甲基取代的核苷衍生物 |
AU2014302711A1 (en) | 2013-06-26 | 2015-12-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9422322B2 (en) | 2013-06-26 | 2016-08-23 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
JP6562908B2 (ja) | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク. | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
EA201692473A1 (ru) | 2014-06-24 | 2017-03-31 | Элиос Биофарма, Инк. | Способы получения замещенных нуклеотидных аналогов |
LT3160476T (lt) | 2014-06-24 | 2021-04-12 | Janssen Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme |
CA2952959C (en) | 2014-06-24 | 2023-03-07 | Alios Biopharma, Inc. | Use of nucleosides and nucleotides to treat filoviridae viral infection |
US20160022724A1 (en) | 2014-07-22 | 2016-01-28 | Alios Biopharma, Inc. | Methods for treating paramyxoviruses |
CA2957017A1 (en) | 2014-08-05 | 2016-02-11 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
CN107108681B (zh) | 2014-10-28 | 2021-04-06 | 詹森生物制药有限公司 | 制备取代的核苷类似物的方法 |
MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
EP3497111A2 (en) | 2016-08-12 | 2019-06-19 | Janssen BioPharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
WO2018081449A1 (en) | 2016-10-27 | 2018-05-03 | Alios Biopharma, Inc. | Methods for treating respiratory syncytial virus infection |
-
2014
- 2014-10-09 JP JP2016521765A patent/JP6562908B2/ja active Active
- 2014-10-09 SG SG11201602595TA patent/SG11201602595TA/en unknown
- 2014-10-09 MX MX2016004558A patent/MX2016004558A/es unknown
- 2014-10-09 CN CN201480064612.5A patent/CN105829333A/zh active Pending
- 2014-10-09 US US14/510,451 patent/US9862743B2/en active Active
- 2014-10-09 KR KR1020167011883A patent/KR102314960B1/ko active IP Right Grant
- 2014-10-09 EA EA201690526A patent/EA201690526A1/ru unknown
- 2014-10-09 CA CA2927010A patent/CA2927010C/en active Active
- 2014-10-09 WO PCT/US2014/059849 patent/WO2015054465A1/en active Application Filing
- 2014-10-09 EP EP14851776.6A patent/EP3055319A4/en active Pending
- 2014-10-09 CN CN202110968375.7A patent/CN113712989A/zh active Pending
- 2014-10-09 SG SG10201804835VA patent/SG10201804835VA/en unknown
- 2014-10-09 AU AU2014331863A patent/AU2014331863C1/en active Active
- 2014-10-09 TW TW103135252A patent/TW201524990A/zh unknown
- 2014-10-09 PE PE2016000494A patent/PE20160658A1/es unknown
-
2016
- 2016-04-07 CL CL2016000805A patent/CL2016000805A1/es unknown
- 2016-04-08 MX MX2021001573A patent/MX2021001573A/es unknown
- 2016-04-10 IL IL245014A patent/IL245014B/en unknown
- 2016-04-11 PH PH12016500660A patent/PH12016500660A1/en unknown
-
2017
- 2017-10-23 US US15/790,764 patent/US10370401B2/en active Active
-
2019
- 2019-01-08 AU AU2019200096A patent/AU2019200096B2/en active Active
-
2020
- 2020-12-03 AU AU2020281091A patent/AU2020281091A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3055319A4 (en) | 2018-01-10 |
CN113712989A (zh) | 2021-11-30 |
CA2927010C (en) | 2022-06-07 |
SG11201602595TA (en) | 2016-04-28 |
CL2016000805A1 (es) | 2016-09-23 |
US20180044369A1 (en) | 2018-02-15 |
JP2016536288A (ja) | 2016-11-24 |
WO2015054465A1 (en) | 2015-04-16 |
PH12016500660A1 (en) | 2016-06-13 |
TW201524990A (zh) | 2015-07-01 |
US9862743B2 (en) | 2018-01-09 |
MX2016004558A (es) | 2016-07-06 |
AU2014331863C1 (en) | 2019-05-16 |
SG10201804835VA (en) | 2018-07-30 |
AU2019200096B2 (en) | 2020-09-03 |
CN105829333A (zh) | 2016-08-03 |
CA2927010A1 (en) | 2015-04-16 |
US20150105341A1 (en) | 2015-04-16 |
MX2021001573A (es) | 2021-04-28 |
US10370401B2 (en) | 2019-08-06 |
KR20160068849A (ko) | 2016-06-15 |
KR102314960B1 (ko) | 2021-10-19 |
IL245014B (en) | 2021-12-01 |
AU2014331863B2 (en) | 2019-01-17 |
AU2020281091A1 (en) | 2021-01-07 |
EA201690526A1 (ru) | 2017-02-28 |
AU2019200096A1 (en) | 2019-01-31 |
EP3055319A1 (en) | 2016-08-17 |
IL245014A0 (en) | 2016-05-31 |
JP6562908B2 (ja) | 2019-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20160658A1 (es) | Nucleosidos sustituidos, nucleotidos y analogos de los mismos | |
CL2018003492A1 (es) | Hepatitis b agentes antivirales. | |
ECSP15015737A (es) | Análogos de 2'-cloro nucleósido para infección por vhc | |
NI201300107A (es) | Derivados de nucleósidos 2' - sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales. | |
UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
PH12014501283A1 (en) | 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication | |
AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
AR089650A1 (es) | Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales | |
BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
EA201492204A1 (ru) | Нуклеозиды на основе урацила и спирооксетана | |
ECSP099319A (es) | Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus | |
CL2014001641A1 (es) | Compuestos derivados de nucleosidos sustituidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y uso para mejorar o tratar una infeccion viral. | |
PH12014501134A1 (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
PE20120257A1 (es) | Analogos carba-nucleosidicos para tratamiento antiviral | |
UY33097A (es) | DERIVADOS DE (1h-PIRAZOL-5-IL)UREIDOARILO 1,3-DISUSTITUIDOS Y SUS USOS TERAPÉUTICOS | |
BR112015031763A2 (pt) | Compostos, composição farmacêutica e processos para melhorar ou tratar infecção viral e para inibir a replicação de paramixovírus e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
UA117800C2 (uk) | Похідні урацилу або тиміну для лікування гепатиту с | |
CO6561783A2 (es) | Inhibidores del virus flaviviridae | |
ECSP12012104A (es) | Inhibidores de virus flaviviridae | |
BR112018011788A2 (pt) | formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação | |
DOP2013000017A (es) | Procesos para preparar compuestos antivirales | |
UY34066A (es) | Inhibidores del virus de la hepatitis c | |
BR112013025236A2 (pt) | derivados de tieno [2,3-d)pirimidina e seu uso no tratamento de arritmia | |
EA201590006A1 (ru) | Комбинация терапевтических средств для лечения инфекции, вызванной вирусом гепатита c |